Background {#Sec1}
==========

Osteodysplasia of the oral and maxillofacial bone is generally accompanied by systemic metabolic bone disease or other systemic abnormalities, such as cardiac malformations or neurological disorders \[[@CR1]--[@CR3]\]. Acquired local osteodysplasia without metabolic disease is usually accompanied by the presence of abnormal soft tissues, including malignant tumors \[[@CR3]\]. However, acquired local osteodysplasia is rarely reported.

The relative affordability and accessibility of genome-wide sequencing have facilitated the development of family-based genomic analysis, resulting in an explosion of gene discovery and diagnosis of rare diseases \[[@CR4]\]. However, for many congenital malformations, identification of the causative mutation by whole-genome sequencing or whole-exome sequencing (WES) has been challenging \[[@CR5]\]. Nonetheless, recent studies have identified specific gene variants in patients with congenitally acquired skeletal disorders, and genome-wide sequencing is a potent technique for the identification of variants implicated in unknown disorders \[[@CR6]\].

Here, we performed WES in a patient with a potentially unknown skeletal disorder involving oral and maxillofacial acquired local osteodysplasia without metabolic disease or soft tissue around the bone lesions.

Case presentation {#Sec2}
=================

Case history {#Sec3}
------------

In 2015, a 46-year-old woman presented to the Department of Oral and Maxillofacial Surgery of Tokai University Oiso Hospital, Kanagawa, Japan, with the complaint of gradually moving mandibular teeth (for 6 months) and changing facial appearance. She had been referred by her family dentist, who had noticed the early stages of mandibular bone loss 9 years prior. She had received no treatment other than periodontal therapy performed by her dentist.

Family history {#Sec4}
--------------

The patient was the youngest of two children. Her mother and father were 32 and 36 years old, respectively, at the time of her birth. Her father died in an accident at the age of 40. Her sister did not exhibit similar symptoms or present with facial malformation.

Medical history {#Sec5}
---------------

Birth weight and intelligence level were normal. The patient's history was remarkable for 10 episodes of bacterial meningitis, which occurred between 31 and 39 years of age. She was premenopausal at presentation.

Physical findings {#Sec6}
-----------------

We consulted an orthopedic surgeon and genetic physician with the intent of performing a comprehensive screening for systemic disorders. Upon skeletal examination, there were no abnormal findings outside of the oral and maxillofacial area; the patient had a height of 157 cm and bone mineral density (according to dual energy x-ray absorptiometry) of 90%. Results of blood and urine tests for bone metabolism markers, including calcium (9.8 mg/dL), phosphorous (4.4 mg/dL), alkaline phosphatase (284 IU), 25-OH-Vitamin D (55 pg/mL), and collagen cross-linked N-telopeptide (18.4 nmol), as well as neurological and cardiovascular examinations, were normal.

Extraoral examination revealed mandibular hypoplasia but no asymmetry (Fig. [1](#Fig1){ref-type="fig"}a). Intraoral examination revealed an anterior open bite (inter-incisor distance: 23 mm) and no crowding of the mandibular teeth. There were no abnormal findings pertaining to the oral mucosa (Fig. [1](#Fig1){ref-type="fig"}b).Fig. 1Patient imaging data. **a** Photographs from extraoral examination reveal mandibular hypoplasia but no asymmetry. **b** Photographs from intraoral examination reveal an anterior open bite (inter-incisor distance: 23 mm) and early contact of the second molars. The upper teeth are crowded without a cleft palate; the lower teeth are not crowded

Radiographic findings {#Sec7}
---------------------

Posteroanterior and lateral radiographs of the skull did not reveal any abnormal morphology of the head or facial height and width (Fig. [2](#Fig2){ref-type="fig"}a). Panoramic radiographic images and computed tomography scans showed axial and coronal thinning of the alveolar bone, anterior wall of the maxillary sinus in the maxilla, and the entire mandibular (condyle, angle, body, and alveolar) bone (Figs. [2](#Fig2){ref-type="fig"}b and [3](#Fig3){ref-type="fig"}). Magnetic resonance imaging did not show any soft tissue masses in the maxillofacial area (data not shown). Technetium (99mTc) bone scintigraphy showed tracer uptake in the maxillary and mandibular bones (Fig. [4](#Fig4){ref-type="fig"}).Fig. 2X-ray images. **a** Posteroanterior and lateral skull views do not reveal morphological abnormalities of the head or face height and width. **b** A panoramic radiographic image shows axial and coronal thinning of the alveolar bone in the maxilla and the entire mandibular (condyle, angle, body, and alveolar) boneFig. 3Computed tomography imaging. Imaging shows axial and coronal thinness of the alveolar bone, anterior wall of the maxillary sinus in the maxilla, and the entire mandibular (condyle, angle, body, and alveolar) boneFig. 499mTc bone scintigraphy shows tracer uptake in the maxillary and mandibular bones

DNA extraction, library preparation, and sequencing {#Sec8}
---------------------------------------------------

Genomic DNA was extracted from 100 μL of whole blood from the patient and her mother (as a negative control) using the DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany) following the manufacturer's recommendations. Initial DNA sample quality assessment, library preparation, and sequencing were conducted by GENEWIZ, Inc. (South Plainfield, NJ, USA). The SureSelectXT Target Enrichment System for Illumina Paired-End Multiplexed Sequencing Library and SureSelect Human All Exon V6 bait library (Agilent, Santa Clara, CA, USA) were used for target enrichment and DNA library preparation following the manufacturer's recommendations.

The sequencing library was loaded onto an Illumina HiSeq instrument (San Diego, CA, USA) according to the manufacturer's instructions. Raw sequence data (.bcl files) generated from the Illumina HiSeq instrument were converted into fastq files and de-multiplexed using bcl2fastq software 2.17 (Illumina). One mismatch was allowed for index sequence identification. The data of whole exome sequence was assigned on The DNA Data Bank of Japan Center (NBDC number: hum0190) \[[@CR7]\].

The average coverage depth of the entire panel was 137×, and 99.9% of targeted bases were covered by sequence reads at a depth of at least 20 × .

Candidate gene approach and gene annotation {#Sec9}
-------------------------------------------

Sequence reads were aligned using BWA (version 0.7.12) \[doi:10.1093/bioinformatics/btp324\]. Local realignment and base quality recalibration was performed using GATK (version 3.5) \[doi: 10.1101/g.107524.110\]. Variant calling was performed with SAMtools (version 1.3.1) \[[doi.org/10.1093/bioinformatics/btp352](http://doi.org/10.1093/bioinformatics/btp352)\] \[[doi.org/10.1093/bioinformatics/btr509](http://doi.org/10.1093/bioinformatics/btr509)\]. Variants were annotated using the ANNOVAR tool \[doi: 10.1093/nar/gkq603\].

Only non-synonymous sequence differences between the mother and patient in the sequenced genes were analyzed. Candidate gene sequencing revealed 83 heterozygous variants in 79 genes, which were confirmed by Sanger sequencing (Table [1](#Tab1){ref-type="table"}). These single-nucleotide variants (SNVs) were not present in any of the queried population databases \[(Integrative Japanese Genome Variation Databas (iJGVD), The International Genome Sample Resource and Providing ongoing support for the 1000 Genomes Project data (1000 Genomes), The Exome Aggregation Consortium (ExAC), snp138, Human Genetic Variation Database (HGVD), and The Genome Aggregation Database (gnomAD)\]. Among the 83 heterozygous variants, 12 SNVs in 11 genes (*AHNAK, CCDC15, COBL, DCAF5, MCF2L, NSRP1, NSRP1, PCNT, RMDN3,* and *TTYH2*) were considered to be "probably damaging" according to Polymorphism Phenotyping v2 (PolyPhen-2) (<http://genetics.bwh.harvard.edu/pph2/>) and Combined Annotation Dependent Depletion (CADD) \[<https://cadd.gs.washington.edu/>\]. These databases predict the potential effect of an amino acid substitution on the structure and function of a human protein using straightforward physical and comparative considerations \[[@CR8]\].Table 1Detected nonsynonymous variants in the patient revealed by candidate gene sequencing and confirmed by Sanger sequencingChromosomeStartEndRefseqAltered sequenceGene symbolExonic mutation typechr26974609669746096TCAAK1nonsynonymous SNVchr1229694116229694116CGABCB10nonsynonymous SNVchr7150728344150728344GTABCB8nonsynonymous SNVchr74561428245614282CGADCY1nonsynonymous SNVchr116229835162298351CGAHNAKnonsynonymous SNVchr57492151374921513CAANKDD1Bnonsynonymous SNVchr51064989710649897GAANKRD33Bnonsynonymous SNVchr5112175876112175876CTAPCstopgainchr5112175918112175918AGAPCnonsynonymous SNVchr5148980794148980794GTARHGEF37nonsynonymous SNVchr3130569767130569767GAATP2C1nonsynonymous SNVchr115353921535392GAC1orf233nonsynonymous SNVchr11124829898124829898CACCDC15nonsynonymous SNVchr114678469446784694GTCKAP5stopgainchr4141315195141315195CACLGNstopgainchr75109280651092806CACOBLnonsynonymous SNVchr41500545015005450GACPEB2nonsynonymous SNVchr205607537456075374GTCTCFLnonsynonymous SNVchr125822081958220819AGCTDSP2nonsynonymous SNVchr125822082758220827GCCTDSP2nonsynonymous SNVchr145910497359104973CADACT1nonsynonymous SNVchr146958906269589062CADCAF5nonsynonymous SNVchr48853627788536277CADSPPnonsynonymous SNVchr173710138337101383GTFBXO47nonsynonymous SNVchr123279181132791811AGFGD4nonsynonymous SNVchr4123748237123748237GTFGF2stopgainchr64156566741565667GTFOXP4nonsynonymous SNVchr6146678724146678724CTGRM1nonsynonymous SNVchr9135553823135553823ACGTF3C4nonsynonymous SNVchrX8037047280370472ACHMGN5nonsynonymous SNVchr204303470443034704CAHNF4Anonsynonymous SNVchr7141401904141401904GTKIAA1147nonsynonymous SNVchr16609185066091850T--LEPRframeshift deletionchr48390535883905358TCLIN54nonsynonymous SNVchr2100938297100938297GALONRF2nonsynonymous SNVchr5121406215121406215CALOXnonsynonymous SNVchr15101606383101606383CALRRK1nonsynonymous SNVchr13113718710113718710CGMCF2Lnonsynonymous SNVchr118616139086161390TCME3nonsynonymous SNVchr57996109379961093CAMSH3nonsynonymous SNVchr3130947458130947458G--NEK11frameshift deletionchr35279760452797604CTNEK4nonsynonymous SNVchrX1739400217394002CTNHSnonsynonymous SNVchr172850626728506267GANSRP1nonsynonymous SNVchr172850794128507941CANSRP1nonsynonymous SNVchr1169131286913128TAOR2D2nonsynonymous SNVchr6163733852163733852ATPACRGnonsynonymous SNVchr6163733870163733870GCPACRGnonsynonymous SNVchr214778375547783755TCPCNTnonsynonymous SNVchr12118574117118574117GTPEBP1nonsynonymous SNVchr16405925464059254GTPGM1nonsynonymous SNVchr3111688538111688538CAPHLDB2nonsynonymous SNVchr145318483553184835GTPSMC6nonsynonymous SNVchr204919645249196452C--PTPN1stopgainchr22049741020497410CAPUM2nonsynonymous SNVchr19913148913148GTR3HDM4nonsynonymous SNVchr178000954080009540GTRFNGnonsynonymous SNVchr154104368541043685TARMDN3nonsynonymous SNVchr194767313947673139CTSAE1nonsynonymous SNVchr195015430850154308CASCAF1nonsynonymous SNVchr33867453338674533GASCN5Anonsynonymous SNVchr79422730794227307GTSGCEnonsynonymous SNVchr213812026538120265CASIM2nonsynonymous SNVchr634567423456742GASLC22A23nonsynonymous SNVchr1158590126158590126TASPTA1nonsynonymous SNVchr24581290445812904CASRBD1stopgainchr137590053275900532CTTBC1D4nonsynonymous SNVchr14104431776104431776GATDRD9nonsynonymous SNVchr82300328423003284GCTNFRSF10Dnonsynonymous SNVchr82300328523003285TATNFRSF10Dnonsynonymous SNVchr3189590767189590767GTTP63nonsynonymous SNVchr33915247039152470AGTTC21Anonsynonymous SNVchr2179417341179417341GTTTNnonsynonymous SNVchr2179590749179590750GG--TTNframeshift deletionchr177224641372246413CTTTYH2nonsynonymous SNVchr168480616984806170CT--USP10frameshift deletionchr34934990149349901CTUSP4nonsynonymous SNVchr57637335476373354GTZBED3nonsynonymous SNVchr2187364925187364925CAZC3H15nonsynonymous SNVchr9109688202109688202AGZNF462nonsynonymous SNVchr99953707099537070CAZNF510nonsynonymous SNVchr56062863460628634GAZSWIM6nonsynonymous SNV

The 11 genes with probably damaging SNVs were analyzed using the Genecards*®* human gene database version 4.5 \[<https://www.genecards.org/>\]. AHNAK may be involved in diverse processes such as blood-brain barrier formation, cell structure and migration, cardiac calcium channel regulation, and tumor metastasis \[[@CR9]\]. COBL may play a role in maintaining intestinal homeostasis \[[@CR10]\]. NSRP1 is an mRNA binding protein that has not been associated with any clinical features \[[@CR11]\]. The molecular and clinical functions of CCDC15, DCAF5, and RMDN3 have not been clarified according to Genecards*®*. MCF2L is related to the Rho/Rac signaling pathways, which play key roles in cell proliferation, migration, and motility, including in cancer metastasis \[[@CR12]\]. Among the 11 genes, only *PCNT* is expressed in the cortex and skeletal muscle. We speculate that the *PCNT* variant (chr21 47783755: NM_006031, exon14, c.2515 T \> C, p.839C \> R; NM_001315529, exon 14, c.2161 T \> C, p.721C \> R) in the patient may affect the cell division of osteoblasts or osteoclasts and bone homeostasis in the oral and maxillofacial area. This differs from the result of *PCNT*-null disorders (Fig. [5](#Fig5){ref-type="fig"}a). Thus, we considered *PCNT* a candidate gene for this disorder because of its high mRNA expression in the cortex and skeletal muscle and the lack of clinical reports for *AHNAK, CCDC15, COBL, DCAF5, MCF2L, NSRP1, NSRP1, RMDN3*, and *TTYH2*. Notably, p.C721R/p.C839R of PCNT has not yet been reported as a candidate variant for skeletal disorders in the Nosology and Classification of Genetic Skeletal Disorders, which serves as a "master" list of genetic disorders of the skeleton to facilitate diagnosis and to help delineate variants or newly recognized conditions \[[@CR13]\].Fig. 5Missense variant present in exon 14. The variant was determined to be *PCNT*: NM_006031, exon 14, c.T2515C, p.C839R; NM_001315529, exon 14, c.T2161C, p.C721R. **a** Sanger sequencing results for the patient and her mother. **b** Mutation map of two isoforms (transcript variants)

Treatment and follow-up {#Sec10}
-----------------------

Because this osteolytic disorder had not been previously reported and no specific treatment was indicated, the patient was placed under observation with periodontal maintenance. No progression has been noted in the 2.5 years since diagnosis.

Discussion and conclusions {#Sec11}
==========================

Osteolysis in the oral and maxillofacial bones can be a phenotype of various systemic disorders, calcium and phosphorus disorders, hyperparathyroidism, hypoparathyroidism, osteomalacia, osteopenia, osteoporosis, Paget's disease, and vitamin D deficiency \[[@CR1], [@CR3], [@CR6], [@CR13], [@CR14]\]. Congenital osteolysis is often hereditary and accompanied by disturbances in bone metabolism \[[@CR14]\]. Major osteolysis can lead to skeletal malformations, such as short stature. Although familial osteodysplasia localized in the mandible was reported in four of six siblings (13 to 23 years old) in 1972, none of the patients had any offspring, and the genetic characteristics of this disease were not investigated \[[@CR15]\].

Potential differential diagnoses of osteodysplasia syndromes, which involve bone anomalies in the oral and maxillofacial region, are shown in Table [2](#Tab2){ref-type="table"} \[[@CR6], [@CR16]\]. Gorham's disease is an acquired condition characterized by local or massive osteolysis that can involve the oral and maxillofacial bones. In this disease, the osteolytic region is often accompanied by soft hemangiomatous or lymphangiomatous tissue \[[@CR6]\]. In our patient, although osteolysis was shown to be localized in the oral and maxillofacial region, soft tissue did not appear around the bone lesions. Hence, we were not able to make a diagnosis based on clinical features. Therefore, we performed WES in the patient and her mother, who did not have a bone disorder, and sought to identify gene variants in known skeletal disorder genes and to clarify the genetic basis of this maxillofacial osteolysis.Table 2Differential diagnoses of osteodysplasia syndromes, which involve bone anomalies in the oral and maxillofacial regionFamilial or notDisruption of genesCongenital or acquiredCommon sites of osteolysisFeatures except ostelysisSporadicNoneAcquiredShoulder, Pelvis (not systemic)Pain, swelling (systemic inframation)FamilialNOTCH2CongenitalMetacarpal bones, metatarsal bones, forearm bones (often systemic)Short stature, optic atrophy, hearing lossFamilialMAFBCongenitalCarpals, phalanges of the toes (often systemic)Renal failureSporadicNPHS2, ACTN4CongenitalCarpals, phalanges of the toes (not systemic)Renal failure, hypertensionFamilialMMP2CongenitalPhalanges, rib, clavicular (not systemic)Atraumatic painless fractureFamilialNot identifiedCongenitalPhalanges of the fingers (not systemic)Tabes dorsalis, syringomyelia, spinal cord tumorFamilialNot identifiedCongenitalPhalanges of the fingers and toes (not systemic)Skin ulcersFamilialASAH1CongenitalPhalanges of the fingers and toes (not systemic)Painful joint deformity, subcutaneous nodules, hoarsenessFamilialMMP14CongenitalPhalanges of the fingers and toes (not systemic)Short stature, severe joint contractures, peripheral corneal opacities

PCNT is one of the calmodulin-binding proteins expressed in the centrosome. PCNT (\< 370 kDa) contains a series of coiled-coil domains and localizes specifically to the centrosomes throughout the cell cycle \[[@CR17]\]. The protein interacts with the microtubule nucleation component gamma-tubulin and is likely important for normal functioning of the centrosomes, cytoskeleton, and cell-cycle progression. Two transcript variants encoding different isoforms of this gene are annotated in the RefSeq database: NM_001315529.1 and NM_006031.5 \[<https://www.ncbi.nlm.nih.gov/nuccore/NM_001315529.1> and <https://www.ncbi.nlm.nih.gov/nuccore/NM_006031.5>\]. The domain structure and function around p.C721R/p.C839R have not been determined.

Critical mutations such as homozygous or compound heterozygous mutations in *PCNT* are a known cause of microcephalic osteodysplastic primordial dwarfism type II (MOPD II; Mendelian Inheritance in Man: 210720). MOPD II is characterized by birth weight (14.3 ± 7.7 SD below the population mean and head circumference 8.5 ± 2.1 SD below the population mean, as well as a variety of associated systemic bone and dental anomalies, but there are not any actual cut-off values for diagnosis \[[@CR18]--[@CR20]\]. Our patient's features differ from those of individuals with MOPD II. However, as our patient has mandibular hypoplasia (Fig. [1](#Fig1){ref-type="fig"}a), we speculate that this phenotype was secondarily caused by jaw osteolysis, similar to the phenotypes of MOPD II patients with micrognathia and retrognathia \[[@CR18]--[@CR20]\]. Genetic data from 25 German MOPD II patients, including three families of Turkish origin, were used in the first mutational analysis of *PCNT*, which revealed homozygous and compound heterozygous *PCNT*-null mutations (four splice-site mutations, two small insertions, 10 small deletions, and one exon deletion) \[[@CR20]\]. In addition, one Colombian MOPD II patient (nonsense mutation, c.C1468T, in exon 10) and members of one Chinese MOPD II family (small deletions in exons 30 and 41) had apparently homozygous null mutations \[[@CR21], [@CR22]\]. *PCNT*-null fibroblast cells derived from MOPD II patients show that a loss of PCNT function induces abnormal mitotic morphology; however, the pathogenic effect of *PCNT* variants in skeletal disorders remains unclear \[[@CR20]\].

The PCNT protein has two transcriptional isoforms in humans and mice: the full-length pericentrin protein (isoform 1) and an alternatively spliced form that lacks the N-terminal amino acids (isoform 2), the structure of which has not been determined (Fig. [5](#Fig5){ref-type="fig"}b) \[[@CR23]\]. However, the molecular mobility of each isoform has not been determined in humans. In vitro and in vivo assays are necessary to identify the functional effect of p.C721R/p.C839R variant.

Bone biopsy is a useful tool for identifying the mechanism of skeletal disorders and determining treatment. Although bisphosphonates and drugs for primary diseases are used in the treatment of systemic bone disease \[[@CR14], [@CR24], [@CR25]\], local osteolysis does not require particular therapy; however, patients often need reconstructive surgery \[[@CR1], [@CR3], [@CR13], [@CR26]\]. In the patient described herein, we did not perform a biopsy due to the risk of fracture. Thus, this patient was not diagnosed with a novel disorder, and we were unable to perform curative treatment. We consider that dental infection is a serious risk factor for the promotion of osteolysis in this patient and ultimately opted for conservative treatment, with the patient undergoing dental maintenance. Intensive follow up including X ray images if necessary and panoramic X ray is performed once every 3 months. If a mandibular fracture were to appear, reconstructive surgery would be necessary.

The WES results presented in this study suggest that the osteolysis in this patient represents a new disease related to the presence of a variant in *PCNT*. Further investigations are required to determine the function of PCNT and identify the mechanism behind acquired local bone osteolysis.

MOPD II

:   Microcephalic osteodysplastic primordial dwarfism type II

WES

:   Whole exome sequencing
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